Catalyst OrthoScience Inc. (“Catalyst”), a private medical technology company redefining shoulder arthroplasty through simplified, surgeon-focused innovation, today announced the close of $15 million in equity and debt financing, led by RC Capital, with participation from Mutual Capital Partners, Dr. Derace Schaffer, and Western Alliance Bank, Member FDIC.
This latest round of funding strengthens Catalyst’s balance sheet and positions the company to advance its high-growth commercial and clinical programs. With expanding surgeon adoption and growing enthusiasm for its differentiated portfolio — including the recently launched Catalyst Fracture Shoulder System — Catalyst continues to deliver on its mission: simplifying complex procedures without compromising outcomes.
“Catalyst epitomizes what can be accomplished by combining continuous innovation with excellence and employee dedication,” said Dr. Derace Schaffer, physician, entrepreneur and long-time Catalyst investor and board member. “As an investor and board member across many public and private healthcare companies, I’ve seen how important it is for a team to execute with both clinical integrity and operational precision. Catalyst stands out as a company that’s not only building value but protecting it – with the leadership, resources, and investor conviction to succeed regardless of any challenge it may face.”
Dr. Schaffer is a seasoned investor and board director across a diverse range of healthcare ventures. A physician by training and serial entrepreneur by background, he founded, funded, and guided numerous startups to successful outcomes – including public offerings. His long-standing support for Catalyst underscores his confidence in the company’s management team and strategic trajectory.
Dr. Theodore Blaine, orthopedic shoulder surgeon at the Hospital for Special Surgery (HSS) and newly appointed Catalyst board member, commented, “As a surgeon, I’ve been impressed by Catalyst’s commitment to evidence-based design that has earned the enduring support of its investors. The company’s innovations improve patient outcomes while also simplifying surgical workflow. With its disciplined execution, Catalyst is providing a compelling combination of clinical value and efficiency.”
Backed by a strong investor base and a leadership team with a proven record of disciplined growth, Catalyst is well-positioned to continue expanding its footprint across hospital and ambulatory surgery center (ASC) markets — advancing surgeon success, patient outcomes, and the evolution of shoulder arthroplasty.